Disease surveillance and genomic analyses in northeast China identifies the emerging tick-borne Yezo virus in 2% of 988 ...

Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included ...

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and PreventionGAITHERSBURG, Md., Nov. 06, 2024 ...

Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...

Emergent Biosolutions (NYSE:EBS) stock rose 14% post-market Wednesday after the company raised the lower end of its revenue ...

Emergent BioSolutions (EBS) announced that brincidofovir will be included in a clinical trial conducted and sponsored by Panther, under the ...

The Africa Centre Disease Control (CDC), with global health partners, has announced the launch of a "pivotal" clinical trial ...

Tecovirimat (TPOXX) and Brincidofovir, for example, have both been approved to treat smallpox and are also thought to work ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by ...